peter attia tirzepatide How do Semaglutide and work, and why are they transforming diabetes and obesity care worldwide? Join our expert-led webinar to explore the science, clinical evidence, and real-world impact of these breakthrough Do GLP-1 receptor agonists improve

"Tirzepatide effectively reduced drive to eat, as well as food-cue-driven and other-cue-driven eating behavior." Nature Medicine This effect is due to tirzepatides action on both GIP and GLP-1 receptors, which slows gastric emptying, signals fullness to the brain, and improves insulin sensitivity

Compared to other peptide therapies, Ipamorelin is more potent as it can optimize growth hormone release for a longer period of time

In late 2024, Zealand Pharma initiated a phase 2b randomized dose-finding obesity and T2DM + obesity clinical trial (ZUPREME-1 and ZUPREME-2) which will evaluate petrelintides efficacy and safety in individuals with obesity in a larger population ( N = 480) [116]

To test this hypothesis, we again used our in vivo phenomic screening platform